Articles on mental health, weight management, hormone therapy, and the connections between them, written from the exam room rather than the marketing department.
For the first time, Medicare will cover GLP-1 weight loss medications. A clinician's guide to the new bridge program, who qualifies, and how it actually works.
A 2026 Lancet Psychiatry study suggests semaglutide may be associated with fewer severe depression and anxiety outcomes. What it means, and what it does not mean, for whole-person care.
A dual-board NP on why GLP-1 denials happen, what documentation can help, when an appeal is worth it, and what cash-pay options exist if it isn't.
A clinical review of why ADHD stimulants feel weaker in the luteal phase and during perimenopause — with recent research on estrogen, dopamine, and hormone therapy.
Symptoms overlap and often coexist. A dual ANCC board-certified NP on how to tell perimenopause and depression apart, and why treating both usually works best.
Functioning doesn't mean thriving. What high-functioning anxiety looks like, why it's so often missed, and what actually treats it.
Weight and mental health share a powerful two-way relationship. Why treating one without the other often falls short.
Plateaus on Wegovy or Zepbound are common and don't always mean the medication has stopped working. What to check and what to do.